Even more, our results demonstrate that different liver cell lines express and release EIF4A3, and that plasma EIF4A3 levels were significantly higher in HCC patients compared to non‐HCC controls (healthy and NAFLD patients), demonstrating the diagnostic capacity of EIF4A3 levels in liquid biopsy. The gene discussed is EIF4A3; the disease is metabolic dysfunction-associated steatotic liver disease.